Table 5.
First-generation epidermal growth factor receptor tyrosine kinase inhibitor plus chemotherapy for unselected patients with non-small cell lung cancer
| Ref. | Treatment | Number of patients | Response rate (%) | Median PFS (mo) | Median OS (mo) |
| INTACT-1[37] | CDDP + GEM + placebo | 363 | 47 | 6 | 10.9 |
| CDDP + GEM + gefitiniba | 365 | 51 | 5.8 | 9.9 | |
| CDDP + GEM + gefitinibb | 365 | 50 | 5.5 | 9.9 | |
| INTACT-2[38] | CDDP + PTX + placebo | 345 | 29 | 5.0 | 9.9 |
| CDDP + PTX + gefitiniba | 345 | 30 | 5.3 | 9.8 | |
| CDDP + PTX + gefitinibb | 347 | 30 | 4.6 | 8.7 | |
| TRIBUTE[39] | CDDP + PTX + placebo | 540 | 19 | 4.9 | 10.5 |
| CDDP + PTX + erlotinib | 539 | 22 | 5.1 | 10.6 | |
| TALENT[40] | CDDP + GEM + placebo | 586 | 30 | 5.6 | 10.1 |
| CDDP + GEM + erlotinib | 586 | 32 | 5.4 | 9.9 |
a
Dose of gefitinib is 250 mg;
b
Dose of gefitinib is 500 mg. EGFR-TKIs: Epidermal growth factor receptor tyrosine kinase inhibitors; NSCLC: Non-small cell lung cancer; PFS: Progression-free survival; OS: Overall survival; CDDP: Cisplatin; GEM: Gemcitabine; PTX: Paclitaxel.